Stent Pioneer Richard A. Schatz, M.D. Joins Cardium's Scientific Advisory Board
|
|
May 1, 2008 -- San Diego -- Cardium Therapeutics (Amex: CXM) announced today that Richard A. Schatz, M.D., has joined its Scientific Advisory Board.
Richard
A. Schatz, M.D. |
|
Dr. Schatz is an early
pioneer of coronary stent technology and is best known for
the co-development of the first successful coronary stent,
the Palmaz-Schatz stent.
Dr. Schatz is Research Director
of Cardiovascular Interventions at the Heart, Lung, and
Vascular Center at Scripps Clinic in La Jolla, California.
He is also
active in gene and stem cell therapy research and teaches
and lectures worldwide. |
" We are very pleased to have Richard Schatz join our scientific advisory board," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium. "Richard is not only a pioneer in the development of vascular stents but has been involved in landmark studies related to new therapies for treating cardiovascular disease. We look forward to benefiting from his expert insights and years of experience in the field of interventional cardiology as we move forward in the development of our lead product candidate, Generx, for the potential treatment of recurrent angina associated with coronary heart disease."
About Cardium
Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies,
Inc. and the Tissue Repair Company, are medical technology companies
primarily focused on the development, manufacture and sale of innovative
therapeutic products and devices for cardiovascular, ischemic and
related indications. Cardium's lead product candidate, Generx™ (alferminogene tadenovec, Ad5FGF4), is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. For more information about Cardium and its businesses, products and therapeutic candidates, please visit http://www.cardiumthx.com or view its 2007 Annual Report at http://www.cardiumthx.com/flash/pdf/CardiumAR07_Book_FINAL.pdf.
Cardium's InnerCool Therapies subsidiary is a San Diego-based medical
technology company in the emerging field of patient temperature
modulation therapy to rapidly and controllably cool the body in
order to reduce cell death and damage following acute ischemic
events such as cardiac arrest or stroke, and to potentially lessen
or prevent associated injuries such as adverse neurological outcomes.
For more information about Cardium's InnerCool subsidiary and patient
temperature modulation, including InnerCool's Celsius Control System™, which has received regulatory clearance in the U.S., Europe and Australia, and the CoolBlue™ System, please visit http://www.innercool.com.
Cardium's Tissue Repair Company subsidiary (TRC) is a San Diego-based
biopharmaceutical company focused on the development of growth
factor therapeutics for the treatment of severe chronic diabetic
wounds. TRC's lead product candidate, Excellarate™, is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate is initially being developed to be administered once or twice for the potential treatment of non-healing diabetic foot ulcers. Other potential applications for TRC's Gene Activated Matrix™ (GAM™) technology include therapeutic angiogenesis (cardiovascular ischemia, peripheral arterial disease) and orthopedic products, including hard tissue (bone) and soft tissue (ligament, tendon, cartilage) repair. For more information about Cardium's Tissue Repair Company subsidiary, please visit http://www.t-r-co.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed
in this press release are forward looking and reflect numerous
assumptions and involve a variety of risks and uncertainties, many
of which are beyond our control and may cause actual results to
differ materially from stated expectations. For example, there
can be no assurance that our scientific advisors and other key
personnel will effectively assist in the development of our business
or product candidates, that our products or product candidates
will prove to be sufficiently safe and effective or will not be
unfavorably compared to competitive products that may be regarded
as safer, more effective, easier to use or less expensive, that
results or trends observed in one clinical study will be reproduced
in subsequent studies, that third parties on whom we depend will
behave as anticipated, or that necessary regulatory approvals will
be obtained. Actual results may also differ substantially from
those described in or contemplated by this press release due to
risks and uncertainties that exist in our operations and business
environment, including, without limitation, our limited experience
in the development, testing and marketing of therapeutic hypothermia
devices and whether our efforts to launch new devices and systems
will be successful or completed within the time frames contemplated,
risks and uncertainties that are inherent in the conduct of human
clinical trials, including the timing, costs and outcomes of such
trials, our dependence upon proprietary technology, our history
of operating losses and accumulated deficits, our reliance on collaborative
relationships and critical personnel, and current and future competition,
as well as other risks described from time to time in filings we
make with the Securities and Exchange Commission. We undertake
no obligation to release publicly the results of any revisions
to these forward-looking statements to reflect events or circumstances
arising after the date hereof.
Cardium Therapeutics™ and Generx™ are trademarks of Cardium
Therapeutics, Inc.
Gene Activated Matrix™, GAM™ and Excellarate™ are trademarks of
Tissue Repair Company.
InnerCool Therapies®, InnerCool®, Celsius Control System™,
RapidBlue™, CoolBlue™ and Accutrol™ are trademarks of InnerCool
Therapies, Inc.
Source: Cardium Therapeutics, Inc.
|